Omacor

Subscribe to Selected New Research on Omacor

22 relevant articles (2 outcomes, 8 trials/studies) found for this Drug

Description: a drug containing the n-3 fatty acids corrects plasma lipid

Also Known As:

P-OM3 adjunct

Relationship Network

Drug Context: Research Results

Experts

1.	MacFadyen, Robert J: 1 article (10/2006)
2.	Lip, Gregory Y H: 1 article (10/2006)
3.	Hamaad, Ali: 1 article (10/2006)
4.	Kaeng Lee, W: 1 article (10/2006)
5.	Ducobu, J: 1 article (09/2005)
6.	Calabresi, L: 1 article (02/2000)
7.	Franceschini, G: 1 article (02/2000)
8.	Sirtori, C R: 1 article (02/2000)
9.	Pazzucconi, F: 1 article (02/2000)
10.	Donati, D: 1 article (02/2000)

Related Diseases

1.	Hypertriglyceridemia 10/01/1997 - "Safety and efficacy of Omacor in severe hypertriglyceridemia." 07/01/2009 - "At higher dosages (daily, 3-4 g) Omacor(R) exhibits more pronounced cardiovascular benefits and, as a licensed indication, improves hypertriglyceridemia and related lipid parameters." 08/21/2006 - "Omacor provides a safe, effective, well-tolerated approach to management of hypertriglyceridemia." 10/01/1997 - "CONCLUSIONS: Four capsules of Omacor per day markedly decreased triglyceride concentrations in patients with severe hypertriglyceridemia. " 07/01/2007 - "OBJECTIVE: This study evaluated the effects on non-HDL-C and other variables of adding prescription omega-3-acid ethyl esters (P-OM3; Lovaza, formerly Omacor [Reliant Pharmaceuticals, Inc., Liberty Corner, New Jersey]) to stable statin therapy in patients with persistent hypertriglyceridemia. " Order ALL the reference details at left...
2.	Inflammation 01/01/2006 - "CONCLUSIONS: Three-month supplementation of Omacor at 1 g per day in post-MI patients is not associated with an improvement in the levels of peripheral indices of coagulation potential, endothelial function, platelet reactivity and inflammation." Order ALL the reference details at left...
3.	IGA Glomerulonephritis (IGA Nephropathy) 09/01/2006 - "Omacor also was used in the North American IgA Nephropathy Study. " 09/01/2006 - "Data from a previously reported randomized 2-yr clinical trial in which two dosages of an ethyl ester omega-3 PUFA (Omacor) were given to 73 high-risk patients with IgA nephropathy were reviewed. " 11/01/1996 - "This includes a brief description of a three-arm multicenter, placebo-controlled study evaluating alternate-day prednisone and highly purified fish oil concentrate (Omacor) in children and young adults with moderately severe forms of IgA nephropathy." 02/01/2004 - "Twenty-three adult patients with biopsy proven IgA nephropathy, with proteinuria more than 1 g/day, serum creatinine less than 3 mg/dl and blood pressure control less than 130/80 mmHg were given omega-3 polyunsaturated fatty acids (PUFA) in the form of an Omacor capsule 4 g/day equivalent to eicosapentaenoic acid (EPA) 1.88 g and docosahexaenoic acid (DHA) 1.48 g for 6 months. " Order ALL the reference details at left...
4.	Body Weight (Weight, Body) 09/01/2006 - "Conversely, increasing levels of lipid parameters were observed with increasing dosages of Omacor (EPA+DHA) in grams per kilogram of body weight at 6 wk of treatment. " 11/01/2006 - "A similar relationship was observed between urine protein/creatinine ratio and dosage of Omacor per kilogram of body weight in trial 2 (r = -0.38, P < 0.001). " 09/01/2006 - "Parameters included body weight; body mass index (BMI); plasma phospholipid AA, EPA, and docosahexanoic acid (DHA) levels and serum creatinine and 24-h urine protein (UP) levels during the 2-yr trial; and time to ESRD after 6.4 yr. Plasma phospholipid levels of EPA, DHA, and EPA/AA ratios were significantly inversely correlated with increasing body weight and BMI in the Omacor 4-g dosage group but not in the Omacor 8-g dosage group. " 11/01/2006 - "In a post hoc analysis of the first trial results, correlations were found between (1) phospholipid eicosapentaenoic acid (EPA)/arachidonic acid (AA) and docosahexaenoic acid (DHA)/AA ratios and the dosage of Omacor, expressed as milligrams per kilogram of body weight (r = 0.78, P < 0.001 for EPA/AA; r = 0.86, P < 0.001 for DHA/AA), (2) phospholipid EPA/AA and DHA/AA levels and percentage change in urine protein/creatinine ratio after 21 to 24 mo of therapy (r = -0.50, P = 0.02 for EPA/AA; r = -0.52, P = 0.01 for DHA/AA), and (3) dosage of Omacor per kilogram of body weight and change in proteinuria after 21 to 24 mo (r = -0.50, P = 0.02). " Order ALL the reference details at left...
5.	Myocardial Infarction 01/01/2009 - "Oral omega-3 ethylester concentrate (omega-3 EEC) [Omacor; Lovaza] is indicated as an adjuvant therapy in adult patients for secondary prevention post-myocardial infarction (MI) and the treatment of hypertriglyceridaemia in the majority of European countries, and for the treatment of hypertriglyceridaemia (serum triglyceride levels > or =5.6 mmol/L [> or =500 mg/dL]) in the US. " 10/01/2006 - "Oral omega n3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in stable post myocardial infarction patients." 01/01/2006 - "Seventy-seven post-myocardial infarction (MI) patients stabilized on standard secondary prevention therapy were randomised either to 3 months' treatment with Omacor 1 g/day (n=37) or 'usual care' control (n=40). " 10/01/2002 - "Omacor is a new omega-3 fatty acid product that is licensed for secondary prevention post-myocardial infarction. " 09/01/2005 - "The polyunsatured fatty acids (PUFA) omega-3 (Omacor) decreases cardiovascular deaths and mainly fatal arrhythmias after myocardial infarction. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Esters
2.	Creatinine
3.	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)
4.	Omega-3 Fatty Acids (Omega 3 Fatty Acids)
5.	Eicosapentaenoic Acid
6.	Lipoproteins (Lipoprotein)
7.	Lipids
8.	Simvastatin (Zocor)
9.	Arachidonic Acid (Vitamin F)
10.	Gemfibrozil (Lopid)

Related Therapies and Procedures

1.	Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
2.	Investigational Therapies (Experimental Therapy)

Best Treatments:
Research Summary Report
on Hypertriglyceridemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 175 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>